Distribution of Soluble Epoxide Hydrolase and of Cytochrome P450 2C8, 2C9, and 2J2 in Human Tissues
Departments of Pharmaceutical Sciences (AEE,MST,DFG) and Pathobiology and Veterinary Science (RAF,MST), University of Connecticut, Storrs, Connecticut
Correspondence to: David F. Grant, 372 Fairfield Road, HGH390 U-92, Storrs, CT 06269. E-mail: david.grant{at}uconn.edu
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key Words: soluble epoxide hydrolase cytochrome P450 human tissues immunohistochemistry
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Since the documentation of the existence of soluble epoxide hydrolase as a different enzyme from the microsomal epoxide hydrolase (Ota and Hammock 1980), its exact physiological substrate(s) and role(s) have been the focus of considerable research. With the many suggested biological roles for sEH, possibly in different tissues, our rationale was to screen whether sEH and P450 epoxygenases exist in these tissues. Many of the biological activities for EETs are regiospecific (Peri et al. 1997
; Node et al. 1999
; Capdevila et al. 2000
). P450s in the arachidonate epoxygenase pathway epoxidize arachidonic acid with distinct regioselectivity (Capdevila et al. 2000
). Hence, the tissue- or organ-specific distribution of these enzymes may be useful in understanding their biological roles in different tissues.
A previous study investigated the distribution of sEH in human tissues by measuring enzyme activity in tissue homogenates, and it has been shown that the liver and kidney have the highest levels of enzyme activity (Pacifici et al. 1988). In this study, using immunohistochemistry (IHC), we provide a comprehensive evaluation of sEH protein localization in an array of normal human tissues and compare distribution and expression levels with those of CYP2C8, 2C9, and 2J2. The results suggest that sEH has a much broader range of expression in humans than has been previously thought, and that CYP2C9 and sEH tissue-specific expression patterns are similar.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
For immunohistochemical (IHC) procedures, 4-µm sections of paraffin-embedded tissues were used. Sections were histologically evaluated with no pathological findings. The tissue microarrays provided a high-throughput method for evaluation of a large number of tissues, and ensured identical experimental conditions and reagent concentrations for all tissues on the same slide.
Polyclonal anti-human sEH rabbit serum specificity was determined by immunoblotting. Polyclonal anti-human CYP2C8 rabbit IgG (Puracyp; Carlsbad, CA) and polyclonal anti-human CYP2C9 rabbit serum (Gentest; Woburn, MA) immunoblotting and specificity were evaluated by the manufacturers. Polyclonal anti-human CYP2J2 rabbit serum (Dr. Zeldin, Laboratory of Pulmonary Pathobiology; NIEHS, National Institutes of Health) specificity has been previously demonstrated by immunoblotting (Wu et al. 1996). Liver sections were used as a positive control for all four antibodies (Pacifici et al. 1988
; Wu et al. 1996
; Lapple et al. 2003
). In addition, the specificity of the antibodies was confirmed by pre-absorption of each primary antibody against the corresponding antigen before incubation with liver sections. sEH was obtained from Baculovirus-infected Sf-21 cells expressing recombinant human sEH [published genomic EPHX2 sequence (Sandberg and Meijer 1996
)], CYP2J2 was a gift from Dr. Zeldin, and CYP2C8 and CYP2C9 were purchased from Gentest.
Electrophoresis and Immunoblotting
Adrenal (175 mg wet weight) and liver (167 mg wet weight) samples were homogenized in 2 ml cold 0.1 M sodium phosphate (pH 7.4), 250 mM sucrose, and 1 mM EDTA and were centrifuged at 13,000 x g (Beckman TL-100 ultracentrifuge) for 25 min. The supernatant fraction from the liver samples was diluted 10-fold. Twenty µl of diluted liver or undiluted adrenal supernatant fraction was added per lane for SDS-PAGE and Western blotting. Protein concentrations were measured by BCA reagent from Pierce (Rockford, IL) as recommended. SDS-PAGE was performed using 5% stacking gels and 10% resolving gels. Proteins were transferred to 0.2-µm PVDF transfer membrane (Millipore; Bedford, MA) overnight at 30V in Tris-glycine buffer with 0.037% SDS and 20% methanol. The membrane was blocked for 1 hr in 5% (w/v) non-fat dry milk plus 0.25% Tween-20 in PBS (pH 7.4), and then incubated with polyclonal rabbit anti-human sEH (1:3000) for 2 hr. The secondary antibody, goat anti-rabbitIgGperoxidase conjugate (1:10,000; Sigma, St Louis, MO) was incubated for 3 hr. Bound secondary antibodies were detected with supersignal chemiluminescent substrate as recommended (Pierce). Bands were visualized with a Kodak image station 440CF, with Kodak 1D software. Baculovirus (Sf-21) cells expressing recombinant human sEH were used as positive controls.
Immunohistochemistry
The Vectastain Elite ABC avidinbiotinalkaline phosphatase kit (Vector Labs; Burlingame, CA) was used. The staining procedure was essentially that provided by the manufacturer. Slides were deparaffinized and hydrated by passage through a series of xylene, ethanol, and distilled water washes. Retrieve-All (Signet; Dedham, MA) was used to unmask antigenic sites as recommended. The sections were then washed in Tris buffer (0.096 M Tris-HCl, 0.029 M Tris base, 0.347 M NaCl with 0.025% Triton X-100, pH 7.6) for 10 min. The sections were incubated with 5% goat blocking serum in Tris buffer for 30 min, and then with primary antibodies (1:25 dilution for sEH, 2C9, and 2J2 antibodies and 1:50 for 2C8 antibody) for 45 min. Primary antibody dilution and incubation period were determined on the basis of titration and optimization experiments. The sections were incubated for 30 min with biotinylated goat anti-rabbit secondary antibody followed by alkaline phosphatase reagent for 30 min. To detect bound antibodies Vector red chromogen was used as substrate. Tris buffer was used for washing between different steps. The sections were then counterstained with hematoxylin, washed in distilled water, and passed through a series of rapid dips in ethanol and xylene, then coverslipped. Negative control studies were done using preimmune rabbit IgG for 2C8 antibody and preimmune rabbit serum for the other primary antibodies, at equivalent concentrations and incubation periods. All experiments were run in replicate (n=25 replicates per experiment) and experiments were repeated on different occasions to confirm constancy of staining in each sample. The expression level of each enzyme in different tissues was evaluated as intensity in stained cells by three independent observers (AE, RF, and MT) and described as absent (-), low (+), moderate (++), or high (+++). Samples from different individuals were assessed for frequency of expression and were expressed as the number of positively stained samples out of the total number of samples for any particular tissue from different individuals.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
|
|
Immunostaining for sEH and 2C9 was detected in blood vessels from many organs and tissues, including cervix (Figure 4D and 4H), uterus, spleen, small intestine, and colon. CYP2J2 (Figure 2K) and sEH (Figure 2B) were also detected in blood vessels of the adrenal gland.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
A comprehensive knowledge of tissue- or cell type-specific patterns of expression of sEH is essential for evaluation of its functional significance, especially with the growing interest in its possible role in many biological activities, including regulation of blood pressure (Sinal et al. 2000), hypertension (Imig et al. 2002
), and vascular inflammation (Node et al. 1999
). A potential role in blood pressure regulation, hypertension, and/or vascular inflammation is supported by our findings demonstrating the expression of sEH and these CYP450s in the kidney, adrenal gland, and blood vessels.
The cell-specific pattern of distribution of sEH and 2J2 in the pancreatic islets is consistent with previous findings for 2J2 (Zeldin et al. 1997), for which it was suggested that EETs regulate the levels of insulin and glucagon (Falck et al. 1983
; Zeldin et al. 1997
). CYP2J2, 2C9, and sEH expression in the pituitary gland is intriguing in light of previous data suggesting the influence of EETs on the release of pituitary hormones such as growth hormone (Snyder et al. 1989
) and prolactin (Cashman et al. 1987
).
Interestingly, different EET regioisomers have differential vasodilator or vasoconstrictor roles (Takahashi et al. 1990; Carroll et al. 1992
; Imig et al. 1996
) as well as differential effects in inflammation (Peri et al. 1997
; Node et al. 1999
; Kozak et al. 2003
). These differential effects may be regulated in different tissues by the patterns of CYP450 epoxygenases, which have been shown to produce different ratios of EET regioisomers (Capdevila et al. 2000
). Furthermore, the level of expression and the distribution pattern of sEH and CYP450 epoxygenases in any particular tissue may alter the availability of arachidonic acid for other pathways in the arachidonic acid metabolic cascade, thus indirectly influencing production of other vasoactive metabolites or proinflammatory metabolites such as prostaglandins.
Finally, sEH has been proposed to play a role in vascular smooth muscle cell and epithelial cell proliferation (Chen et al. 1998; Yu et al. 2000
; Davis et al. 2002
), which is again supported by the widespread distribution pattern in epithelial cells and blood vessels.
In conclusion, as a xenobiotic-metabolizing enzyme, sEH has a widespread pattern of distribution in normal human tissues and may have a particularly important role in xenobiotic metabolism in some tissues such as the pituitary gland, which lacks a bloodbrain barrier and has been previously shown to have higher xenobiotic metabolizing enzyme activities than other parts of the brain (GhersiEgea et al. 1992). The detection of sEH and P450 epoxygenases in a variety of normal human tissues supports the different suggested biological roles in these tissues and organs. CYP450-generated epoxides and their corresponding sEH metabolites would be suggested to act as mediators, the levels of which are regulated by expression levels of these enzymes in different tissues. The three main patterns of distribution identified may determine the differential effects of different epoxide regioisomers in any particular tissue. Moreover, these patterns may have functional significance by altering the availability of arachidonic acid for other pathways. Finally, among the P450s studied here, sEH and 2C9 seem to have the greatest similarities in distribution patterns. Further investigation will be needed to determine the biological significance of these patterns of sEH and CYP450 distribution and the differential effects of metabolites produced by these pathways in different tissues.
![]() |
Acknowledgments |
---|
We are grateful to Dr B. Hammock (University of California, Davis) for providing the polyclonal anti-human soluble epoxide hydrolase rabbit serum and to Dr D. Zeldin (Laboratory of Pulmonary Pathobiology; NIEHS, National Institutes of Health) for providing the polyclonal anti-human CYP2J2 rabbit serum. We also thank Ione Jackman and Lynn Howlett (Histology Laboratory, University of Connecticut) for advice and assistance during the completion of this work.
![]() |
Footnotes |
---|
![]() |
Literature Cited |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bylund J, Kunz T, Valmsen K, Oliw EH (1998) Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes. J Pharmacol Exp Ther 284:5160
Capdevila JH, Falck JR, Harris RC (2000) Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41:163181
Carroll MA, Garcia MP, Falck JR, McGiff JC (1992) Cyclooxygenase dependency of the renovascular actions of cytochrome P450-derived arachidonate metabolites. J Pharmacol Exp Ther 260: 104109[Abstract]
Cashman JR, Hanks D, Weiner RI (1987) Epoxy derivatives of arachidonic acid are potent stimulators of prolactin secretion. Neuroendocrinology 46:246251[Medline]
Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA (1990) Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci USA 87:58935897[Abstract]
Chen JK, Falck JR, Reddy KM, Capdevila J, Harris RC (1998) Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J Biol Chem 273:2925429261
Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, Weiss RH (2002) Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 99:22222227
Draper AJ, Hammock BD (2000) Identification of CYP2C9 as a human liver microsomal linoleic acid epoxygenase. Arch Biochem Biophys 376:199205[Medline]
Falck JR, Manna S, Moltz J, Chacos N, Capdevila J (1983) Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. Biochem Biophys Res Commun 114:743749[Medline]
GhersiEgea JF, LeiningerMuller B, Minn A, Siest G (1992) Drug metabolizing enzymes in the rat pituitary gland. Prog Brain Res 91:373378[Medline]
Imig JD (1999) Epoxyeicosatrienoic acids. Biosynthesis, regulation, and actions. Methods Mol Biol 120:173192[Medline]
Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR (1996) Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7:23642370[Abstract]
Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690694
Kozak W, Aronoff DM, Boutaud O, Kozak A (2003) 11,12-epoxyeicosatrienoic acid attenuates synthesis of prostaglandin E2 in rat monocytes stimulated with lipopolysaccharide. Exp Biol Med 228:786794
Lapple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, et al. (2003) Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 13:565575[Medline]
Meijer J, DePierre JW (1988) Cytosolic epoxide hydrolase. Chem Biol Interact 64:207249[Medline]
Moghaddam MF, Grant DF, Cheek JM, Greene JF, Hammock BD (1997) Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nature Med 3:562566[Medline]
Moran JH, Mitchell LA, Bradbury JA, Qu W, Zeldin DC, Schnellmann RG, Grant DF (2000) Analysis of the cytotoxic properties of linoleic acid metabolites produced by renal and hepatic P450s. Toxicol Appl Pharmacol 168:268279[Medline]
Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:12761279
Ota K, Hammock BD (1980) Cytosolic and microsomal epoxide hydrolases: differential properties in mammalian liver. Science 207:14791481[Medline]
Pacifici GM, Temellini A, Giuliani L, Rane A, Thomas H, Oesch F (1988) Cytosolic epoxide hydrolase in humans: development and tissue distribution. Arch Toxicol 62:254257[Medline]
Peri KG, Varma DR, Chemtob S (1997) Stimulation of prostaglandin G/H synthase-2 expression by arachidonic acid monoxygenase product, 14,15-epoxyeicosatrienoic acid. FEBS Lett 416: 269272[Medline]
Pinot F, Grant DF, Spearow JL, Parker AG, Hammock BD (1995) Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice. Biochem Pharmacol 50:501508[Medline]
Sandberg M, Meijer J (1996) Structural characterization of the human soluble epoxide hydrolase gene (EPHX2). Biochem Biophys Res Commun 221:333339[Medline]
Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275:4050440510
Snyder GD, Yadagiri P, Falck JR (1989) Effect of epoxyeicosatrienoic acids on growth hormone release from somatotrophs. Am J Physiol 256:E221226[Medline]
Takahashi K, Capdevila J, Karara A, Falck JR, Jacobson HR, Badr KF (1990) Cytochrome P-450 arachidonate metabolites in rat kidney: characterization and hemodynamic responses. Am J Physiol 258:F781789[Medline]
Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:34603468
Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, et al. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87: 992998
Zeldin DC, Foley J, Boyle JE, Moomaw CR, Tomer KB, Parker C, Steenbergen C, et al. (1997) Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 138:13381346